IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – Time to Buy?

Shares of IPSEN (OTCMKTS:IPSEY) saw an uptick in trading volume on Tuesday . 10,267 shares were traded during trading, an increase of 447% from the previous session’s volume of 1,878 shares.The stock last traded at $45.91 and had previously closed at $47.60.

Analyst Ratings Changes

Several research firms recently weighed in on IPSEY. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Barclays cut shares of IPSEN from an “equal weight” rating to an “underweight” rating in a report on Tuesday. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

IPSEN Trading Down 6.6%

The company’s 50-day simple moving average is $46.61 and its 200-day simple moving average is $46.76.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).